mRNA encoded Cas9 targeting human KLKB 1 gene therapy (Pharma Gateway)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NamemRNA encoded Cas9 targeting human KLKB 1 gene therapy (Pharma Gateway)
Drug Alias Namekallikrein B1 Cas9 gene therapy (Pharma Gateway)KLKB1 mRNA encoded Cas9 gene therapy (Pharma Gateway)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionPlasma kallikrein inhibitors
TargetsPlasma kallikrein
Therapy Area/IndicationsAngioedemas, Hereditary
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryEurope
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaN/A
Originator CompaniesPharma Gateway AB
China Registration ClassN/A

Develop Information

Active CompaniesPharma Gateway AB
Inactive CompaniesN/A
Active IndicationsAngioedemas, Hereditary
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A